Entrada Therapeutics, INC 10-Q quarterly reports

Entrada Therapeutics reported encouraging early functional data from its ENTR-601-44 Phase 1/2 trial for Duchenne Muscular Dystrophy, while noting a cash runway into Q3 2027.

Entrada Therapeutics announced its first-quarter 2026 financial results, highlighting progress in its Duchenne Muscular Dystrophy (DMD) programs and its collaboration with Vertex Pharmaceuticals.

Entrada Therapeutics reported a significant net loss for the nine months ended September 30, 2025, driven by decreased collaboration revenue and increased R&D expenses, while advancing its Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) clinical programs.

Entrada Therapeutics, a clinical-stage biopharmaceutical company, reported a significant net loss in Q2 2025 due to a sharp decline in collaboration revenue and increased research and development expenses, despite advancing its Duchenne muscular dystrophy pipeline.

Entrada Therapeutics reports a net loss for Q1 2025, focuses on DMD clinical programs, and advances partnered candidate VX-670 with Vertex.

Entrada Therapeutics announced positive preliminary Phase 1 clinical trial data for ENTR-601-44 and plans to submit regulatory applications for Phase 2 trials.

Entrada Therapeutics reports a significant increase in collaboration revenue and net income for the second quarter of 2024, primarily driven by its partnership with Vertex Pharmaceuticals.

Entrada Therapeutics reports a strong first quarter of 2024, highlighted by significant collaboration revenue and progress in clinical development programs.